China, Aug. 27 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Hybrid Melittin Lipid Nanoparticles inhibit ferrocytosis and delay the progression of diabetic kidney disease by modulating the P53/NRF2/SLC7A11 pathway'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600130954
Registration Time: 2026/08/26
Type: Observational study
Primary Sponsor: Zhejiang Provincial People's Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=327987
Published by HT Digital Content Services with permission from Health Daily Digest....